about
Human neoplasms elicit multiple specific immune responses in the autologous hostHLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic RatsThe SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.RNF41 interacts with the VPS52 subunit of the GARP and EARP complexesRP1 is a phosphorylation target of CK2 and is involved in cell adhesionTreatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010).Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort.Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro.Structure-activity profiles of Ab-derived TNF fusion proteins.Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient.Quantitative perfusion analysis of malignant liver tumors: dynamic computed tomography and contrast-enhanced ultrasound.A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases.How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation?Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.Cancer Immunotherapy and the Immune Response in Follicular Lymphoma.Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cellsAutonomic dysfunction in patients with achalasia[A progressive ulcerative neck mass on the left infraauricular area][After care in Hodgkin lymphoma]Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas[New drug treatment possibilities in castration resistant prostate carcinoma]Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the DoorstepTherapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX)Diagnosis and treatment of follicular lymphoma: an update[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
P50
Q24564371-D29F5F98-B693-4DA6-B87F-1AD14C4F6F56Q27303777-F5EA1447-AB9B-47A4-8237-3B72D013166AQ28292213-B03F4125-D954-45DB-A0EB-CBF8D3E6D02EQ34111796-9FD44C56-882B-4A05-ADE4-A4BAA1AE5D1DQ36380788-D8507174-493F-41CF-B2BF-EA9B0A4D20E3Q36981391-CB27A9AF-B6D0-48D8-92F7-520050E9ADDDQ37012044-2A1CE3D7-5CCF-4520-B8C1-4E539C2D69A8Q37764751-3BF8CF75-56EE-4C84-8E25-6DDC7E11AA63Q39079572-E5CFF6EC-4A72-471A-9F77-52E28CB22FDCQ39571137-A0766E6F-E5ED-4135-A1F3-A3CA73199FB4Q40247850-E5A36BDB-F2C4-43DE-AD3B-AA2FD541675CQ42055599-C2DB11F2-D724-47ED-8D15-2A561FD4F2FEQ46001678-17870087-4317-4986-9CCE-CB9A91518D80Q47650946-B9788209-FBA1-4F60-8474-AE11C0A6DD96Q47965235-466AA4DB-DE92-464B-827A-DDF7234E7F6FQ48187625-B1A3F512-35DD-47D8-B9B6-DAB637B102F6Q49377077-FC8519E0-54EC-4CF6-895A-B67A8F75D19BQ49665457-6834D8DB-B009-43B1-A9A1-E1C594AEEF53Q53293535-D381432C-0785-4B32-BB44-125B93FFC65BQ53530315-4DF2C006-1AAF-4F1B-B0B7-172A95F2E6F1Q53659584-19001BB6-B1E2-4B97-98DD-A51553370D39Q53776529-3E005631-0AEA-44EA-A614-6AB0BFC624E7Q54202082-877181CC-F803-4CA0-9CA3-BA0BF2481A5FQ54982526-FADFD6BE-41DA-43B0-9EEA-D171EFA8E32FQ55401659-EF48DC37-1A00-4676-9511-631DA3D43EEAQ55442330-FC3C72B2-CB39-4A76-B72D-A32697F17E5FQ56889933-D9D7F515-B03B-4733-A7E4-44CFA8E5919BQ71939141-C054A89B-64E7-4CB6-8609-49A50F54534BQ82213188-D9B1A347-9049-44B1-9FFF-FDF4E8806A6DQ82914362-9534CB59-0F11-4531-BCE2-56283C78B6DCQ84000592-8C7294AB-E66E-475A-9607-6C1EF13B23DCQ84929549-3DC1EDCD-531D-4AFB-90F0-6D9EBDEE5CD9Q85030943-EF6932D6-4548-4811-B047-BDA5A9CDA731Q85911143-627CDF8B-FF1A-41AD-8341-F6F8DA470AF5Q90198363-96FFECAF-03FC-46C3-895C-D793CA448994Q90465385-34936661-CB4C-479F-92B3-E11056E0EF0AQ91514291-1DFC7419-D19B-4A40-BBA6-103BB7E40BDBQ91593901-7708F3EC-C541-4B9D-B40E-2AE59B0EE91D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frank Stenner
@ast
Frank Stenner
@en
Frank Stenner
@es
Frank Stenner
@nl
type
label
Frank Stenner
@ast
Frank Stenner
@en
Frank Stenner
@es
Frank Stenner
@nl
prefLabel
Frank Stenner
@ast
Frank Stenner
@en
Frank Stenner
@es
Frank Stenner
@nl
P106
P21
P31
P496
0000-0003-4541-8817